ArticleDiscover oncology2026
Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with substantial mortality globally. The synergistic potential between immunotherapy and yttrium-90 transarterial radioembolization (⁹⁰Y-TARE) has stimulated extensive research into HCC combined therapeutic strategies. However, a comprehensive bibliometric analysis elucidating the evolutionary trajectory, research trends, and collaborative networks within this field remains absent. Unlike conventional systematic reviews, which are inherently subjective and lack the capacity for large-scale quantitative synthesis, bibliometric analysis offers a robust, data-driven approach to construct a holistic knowledge atlas. A total of 143 relevant publications were extracted from the Web of Science Core Collection (WoSCC) database, spanning 1 January 2003 to 24 October 2025. Utilizing VOSviewer, CiteSpace, and the R package bibliometrix, a multidimensional analysis encompassing publication volume, journal impact, national/contributions, institutional collaborations, authorship networks, co-citation patterns, and keyword clustering was conducted. From 2015 to 2025, the number of publications in this field has steadily increased. The United States was the dominant contributor. Global institutional collaboration was limited, highlighting the need for multinational cooperation. Co-citation and keyword analyses revealed three research frontiers: mechanisms of radio-immunologic synergy, optimization of treatment sequencing and dosimetry, and predictive biomarker development. Future research requires more phase III trials, incorporating multi-omics technologies and individualized dosimetry models to validate survival benefits and explore more precise immuno-combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.